Literature DB >> 17097331

Metallothioneins I and II: neuroprotective significance during CNS pathology.

Roger K Stankovic1, Roger S Chung, Milena Penkowa.   

Abstract

Metallothioneins (MTs) constitutes a superfamily of highly conserved, low molecular weight polypeptides, which are characterized by high contents of cysteine (sulphur) and metals. As intracellular metal-binding proteins they play a significant role in the regulation of essential metals. The major isoforms of the protein (MT-I and MT-II) are induced by numerous stimuli and pathogens but most importantly their induction by metals is closely linked to the physiological metabolism of zinc and protection from the toxic affects following heavy metal exposure. Although the preservation of their genetic expression across animal phyla suggests that MTs may play an important physiological role, MT-I, II knock out (KO) mice survive to adulthood. In both central and peripheral nervous tissues, MT-I, II have neuroprotective roles, which are also induced by exogenous MT-I and/or MT-II treatment. Hence, MT-I, II may provide neurotherapeutic targets offering protection against neuronal injury and degeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097331     DOI: 10.1016/j.biocel.2006.09.010

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  19 in total

1.  Up-regulation of metallothionein gene expression in parkinsonian astrocytes.

Authors:  Gregory J Michael; Sharmin Esmailzadeh; Linda B Moran; Lynne Christian; Ronald K B Pearce; Manuel B Graeber
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

Review 2.  Drug delivery systems, CNS protection, and the blood brain barrier.

Authors:  Ravi Kant Upadhyay
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

3.  Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice.

Authors:  Shinki Murakami; Ikuko Miyazaki; Norio Sogawa; Ko Miyoshi; Masato Asanuma
Journal:  Neurotox Res       Date:  2014-06-13       Impact factor: 3.911

4.  Glucocorticoids regulate metallothionein-1/2 expression in rat choroid plexus: effects on apoptosis.

Authors:  A Martinho; I Gonçalves; C R Santos
Journal:  Mol Cell Biochem       Date:  2013-01-06       Impact factor: 3.396

5.  Modification of neurobehavioral effects of mercury by genetic polymorphisms of metallothionein in children.

Authors:  James S Woods; Nicholas J Heyer; Joan E Russo; Michael D Martin; Pradeep B Pillai; Federico M Farin
Journal:  Neurotoxicol Teratol       Date:  2013-07-01       Impact factor: 3.763

Review 6.  Metallothionein and the biology of aging.

Authors:  William R Swindell
Journal:  Ageing Res Rev       Date:  2010-10-08       Impact factor: 10.895

7.  Covalent arylation of metallothionein by oxidized dopamine products: a possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival.

Authors:  Michelle A Gauthier; Joseph K Eibl; James A G Crispo; Gregory M Ross
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

8.  Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium.

Authors:  Abhai K Tripathi; Wei Sha; Vladimir Shulaev; Monique F Stins; David J Sullivan
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

9.  Host biomarkers and biological pathways that are associated with the expression of experimental cerebral malaria in mice.

Authors:  Miranda S Oakley; Thomas F McCutchan; Vivek Anantharaman; Jerrold M Ward; Laurence Faucette; Cindy Erexson; Babita Mahajan; Hong Zheng; Victoria Majam; L Aravind; Sanjai Kumar
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

10.  Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.

Authors:  Gouda K Helal; Abdulaziz M Aleisa; Omayma K Helal; Salim S Al-Rejaie; Abdulaziz A Al-Yahya; Abdulhakeem A Al-Majed; Othman A Al-Shabanah
Journal:  Oxid Med Cell Longev       Date:  2009 Jan-Mar       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.